← Eichor
Study identifier: NCT01185132 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

Condition: Breast Cancer  ·  Sponsor: Rocky Mountain Cancer Centers

PhasePhase 3
Planned participants660
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Rachel Lei, BS  ·  303-418-7607  ·  rachel.lei@usoncology.com

Charles Leonard, MD  ·  303-730-4700

Always discuss trial participation with your own doctor first.

Locations (5)

Rocky Mountain Cancer Centers - AuroraAurora, Colorado, United StatesRecruiting
Rocky Mountain Cancer Centers - BoulderBoulder, Colorado, United StatesRecruiting
Rocky Mountain Cancer Centers - LakewoodLakewood, Colorado, United StatesRecruiting
Rocky Mountain Cancer Centers - LittletonLittleton, Colorado, United StatesRecruiting
Rocky Mountain Cancer Centers - ThorntonThornton, Colorado, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01185132